Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 6.96M | 2.82M | 21.05M | 13.54M | 10.14M | 1.08M |
Gross Profit | 6.25M | 2.82M | -67.10M | 8.40M | 6.81M | -19.49M |
EBITDA | -130.55M | -119.74M | -80.10M | -59.91M | -45.30M | -25.00M |
Net Income | -136.78M | -127.50M | -89.22M | -65.81M | -48.63M | -26.02M |
Balance Sheet | ||||||
Total Assets | 298.56M | 371.12M | 272.15M | 199.09M | 188.11M | 49.74M |
Cash, Cash Equivalents and Short-Term Investments | 218.04M | 290.11M | 192.04M | 120.03M | 161.41M | 34.79M |
Total Debt | 64.40M | 97.38M | 92.43M | 85.98M | 6.04M | 7.43M |
Total Liabilities | 121.85M | 130.15M | 121.28M | 99.66M | 27.33M | 92.20M |
Stockholders Equity | 176.71M | 240.97M | 150.87M | 99.43M | 160.78M | -42.46M |
Cash Flow | ||||||
Free Cash Flow | -131.25M | -114.65M | -64.50M | -70.73M | -58.62M | -7.26M |
Operating Cash Flow | -126.18M | -110.82M | -61.36M | -66.50M | -48.68M | -3.02M |
Investing Cash Flow | 6.91M | -52.61M | -60.76M | -4.22M | -9.94M | -4.24M |
Financing Cash Flow | 46.51M | 208.76M | 135.44M | 29.36M | 189.67M | 288.00K |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
49 Neutral | 94.64M | -0.57 | -185.15% | ― | ― | 1.80% | |
48 Neutral | $104.98M | ― | -63.33% | ― | -42.94% | ― | |
45 Neutral | 92.38M | -3.05 | -66.16% | ― | -87.65% | 11.76% | |
37 Underperform | 81.63M | -2.30 | ― | ― | ― | 62.83% | |
32 Underperform | 34.50M | -0.53 | ― | ― | ― | 22.94% | |
30 Underperform | 179.72M | -2.63 | ― | ― | ― | -4.60% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
On September 9, 2025, TScan Therapeutics released an updated corporate presentation outlining revised development and operational milestones, including adjusted timelines for its solid tumor program and updates on its pipeline for hematologic malignancies. The presentation, intended for investors and stakeholders, reflects the company’s ongoing efforts in target discovery initiatives in autoimmunity and highlights its strategic focus on advancing its TCR-T therapy candidates. This update is significant for stakeholders as it provides insights into TScan’s future growth strategies and its potential impact on the biotechnology industry.
The most recent analyst rating on (TCRX) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on TScan Therapeutics stock, see the TCRX Stock Forecast page.